Understanding Your ROI

John Elliott from Carevive delves into the pressing question of ROI in the evolving landscape of value-based care reimbursement models. As the oncology care model (OCM) transitions into the enhancing oncology model, stakeholders are evaluating the technology, processes, and resources that will support their future endeavors.

Carevive proves to be a twofold solution, seamlessly aligning with the current fee-for-service model for chronic care management. By providing tools and solutions to manage symptoms, Carevive aids in avoiding hospitalizations and enhancing patient outcomes, leading to additional revenue and reimbursements for partners.

Moreover, Carevive is firmly positioned to align with the future enhanced oncology model, as it focuses on driving transformation, quality metrics, and health equity advancement. The integration of electronic patient-reported outcomes (ePROs) exemplifies Carevive’s commitment to symptom remote management, a vital component of the future model.

Recent Episodes

In this episode of Inside Restoration & Recovery, host Martha Lewis welcomes Jason McClaren, Director of Facilities Operations at Reunion Rehabilitation Hospitals, to discuss the critical advantage of partnering with a restoration team experienced in healthcare. A former firefighter and military veteran, Jason has spent the last decade managing safety, risk, and emergency preparedness…

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…